New sedative could be safer for frail patients during medical procedures

NCT ID NCT07362173

Ongoing Symptom relief Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares remimazolam, a new ultra-short-acting sedative, to propofol in 200 patients aged 65 or older with serious health conditions. The goal is to see if remimazolam provides better heart and breathing stability during endoscopic procedures. Researchers will also measure patient and doctor satisfaction and recovery quality.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remimazolam
What this could lead to: If successful, remimazolam could become a safer sedation option for elderly or frail patients, reducing complications like low blood pressure or breathing problems.
What could go wrong: This is a phase 4 study with 200 participants, so results may not apply to all patients. Remimazolam is already approved, but the trial focuses on specific high-risk groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE 65 AND OLDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease multiple organ dysfunction syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE 65 AND OLDER ASA CLASS III/IV PATIENTS COPD III/IV MULTIPLE ORGAN FAILURE

Contacts and locations

Locations

Regional Institute of Gastroenterology-Hepatology Prof. Dr. Octavian Fodor

Cluj-Napoca, Cluj, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.